Scientific Updates for Improved Outcomes in Patients with Hepatocellular Carcinoma


Program Dates: March 1, 2019 - February 28, 2020
Credits: 1.0 AMA PRA Category 1 Credit™; 1.0 CNE contact hour


Scientific Updates for Improved Outcomes in Patients with Hepatocellular Carcinoma

Program Overview

This CME/CNE program will provide learners with an update regarding treatment and management of patients with hepatocellular carcinoma (HCC) through an interactive panel format. The expert faculty will first set the stage for modern day HCC care, reviewing the science, prevalence and current treatment guidelines. Recent clinical trial data of first line, second line and combination therapies will be analyzed along with emerging therapeutics, with the clinical implications debated among the panel. Best practices for managing adverse events through an interprofessional approach will be relayed. At the conclusion of this CME/CNE activity, learner’s will be better equipped to implement optimal, team-based care in clinical practice.

Target Audience

Oncologists, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with HCC

Learning Objectives

  1. Analyze recent data of current and emerging therapeutic options for the treatment of HCC
  2. Apply effective treatment strategies to improve outcomes for patients with HCC

Faculty

Abou-AlfaGhassan K. Abou-Alfa, MD (Course Chair)
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

 

 

Screen Shot 2019-02-28 at 10.07.18 AMAlison Clemens, RN, OCN
Memorial Sloan Kettering Cancer Center
New York, New York

 

 

 

 

SingalAmit Singal, MD
Medical Director, Liver Tumor Program
Clinical Chief of Hepatology
UT Southwestern Medical Center
Dallas, Texas

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

FacultyRelationship Identified With:
Ghassan K. Abou-Alfa, MD 
Consultant/Advisor: Agios Pharmaceuticals; Alignmed, Inc.; Amgen Inc.; Antengene Corporation; Aptus Pharma; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer AG; BeiGene; Bioline; Bristol-Myers Squibb Company; Boston Scientific; BridgeBio Inc.; CARsgen Therapeutics; Celgene Corporation; CASI Pharmaceuticals Inc.; Cipla Inc.; CytomX Therapeutics; Daiichi Sankyo; Debio; Delcath Systems Inc.; Eisai Co., Ltd.; Eli Lilly and Company; Exelixis, Inc.; Genoscience Pharma; Gilead Sciences, Inc.; Halozyme, Inc.; Hengrui Therapeuitcs Inc.; Incyte Corporation; Inovio Pharmaceuticals, Inc.; Ispen; Jazz Pharmaceuticals; janssen Pharmaceuticals, Inc.; Kyowa Hakko Kirin Co., Ltd.; Lam Research; Loxo Oncology; Merck & Co.; Minapharm Pharmaceuticals.; NewLink Genetics Corporation; Novella Clinical; Onxeo; PCI Biotech Holding; Pfizer Inc.; PharmaCyte Biotech; Pharmacyclics; Pieris Pharmaceuticals, Inc.; QED Therapeutics; RedHill Biopharma Ltd; Sanofi; Servier; Silenseed Ltd.; SillaJen Biotherapeutics, Inc.;Sobi; Targovax; Tekmira; twoXAR, Incorporated; Vicus Therapeutics; Yakult Pharmaceutical Industry Co., Ltd.; Yiviva, Inc.; 3D Medicines CorporationGrant/Research Support: Acta Biológica; Agios Pharmaceuticals; Array BioPharma; AstraZeneca; Bayer AG; BeiGene; Bristol-Myers Squibb Company; CASI Pharmaceuticals Inc.; Celgene Corporation; Eli Lilly and Company; Exelixis, Inc.; Genentech, Inc.; Halozyme, Inc.; Incyte Corporation; MabVax Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; OncoQuest Inc.; Polaris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; QED Therapeutics; Roche
Alison Clemens, RN, OCN  Nothing to disclose.
 Amit Singal, MD Consultant/Advisor: AbbVie Inc; Bayer AG; Bristol-Myers Squibb Company; Eisai, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Glycotest, Inc.; Roche; Wako Diagnostics U.S.A Corporation

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Emma Boring and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hours). Provider number P0491.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by independent educational grants from Bristol-Myers Squibb Company and Eisai Co., Ltd.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Bristol-Myers Squibb Company and Eisai Co., Ltd. do not recommend the use of any agent outside of the labeled indications

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact [email protected].

BUTTON

Provided by AcademicCME AcademicCME-web